Moreover, the 36-month beta value for CCCC is 3.00. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for CCCC is 58.32M and currently, short sellers hold a 10.04% of that float. On November 15, 2024, CCCC’s average trading volume was 985.80K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CCCC) stock’s latest price update
The stock of C4 Therapeutics Inc (NASDAQ: CCCC) has decreased by -7.99 when compared to last closing price of 5.13.Despite this, the company has seen a loss of -21.85% in its stock price over the last five trading days. zacks.com reported 2024-10-31 that C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.55 per share a year ago.
CCCC’s Market Performance
C4 Therapeutics Inc (CCCC) has seen a -21.85% fall in stock performance for the week, with a -32.57% decline in the past month and a -19.32% plunge in the past quarter. The volatility ratio for the week is 7.94%, and the volatility levels for the past 30 days are at 7.82% for CCCC.. The simple moving average for the past 20 days is -19.25% for CCCC’s stock, with a -26.89% simple moving average for the past 200 days.
Analysts’ Opinion of CCCC
Many brokerage firms have already submitted their reports for CCCC stocks, with JP Morgan repeating the rating for CCCC by listing it as a “Neutral.” The predicted price for CCCC in the upcoming period, according to JP Morgan is $6 based on the research report published on January 29, 2024 of the current year 2024.
Stifel, on the other hand, stated in their research note that they expect to see CCCC reach a price target of $12, previously predicting the price at $2. The rating they have provided for CCCC stocks is “Buy” according to the report published on December 13th, 2023.
Credit Suisse gave a rating of “Neutral” to CCCC, setting the target price at $10 in the report published on February 24th of the previous year.
CCCC Trading at -20.12% from the 50-Day Moving Average
After a stumble in the market that brought CCCC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.27% of loss for the given period.
Volatility was left at 7.82%, however, over the last 30 days, the volatility rate increased by 7.94%, as shares sank -26.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.04% lower at present.
During the last 5 trading sessions, CCCC fell by -21.85%, which changed the moving average for the period of 200-days by -23.62% in comparison to the 20-day moving average, which settled at $5.85. In addition, C4 Therapeutics Inc saw -16.46% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CCCC starting from Salter Malcolm, who proposed sale 13,000 shares at the price of $6.41 back on Oct 18 ’24. After this action, Salter Malcolm now owns shares of C4 Therapeutics Inc, valued at $83,321 using the latest closing price.
Salter Malcolm, the Director of C4 Therapeutics Inc, proposed sale 8,561 shares at $5.38 during a trade that took place back on Oct 11 ’24, which means that Salter Malcolm is holding shares at $46,061 based on the most recent closing price.
Stock Fundamentals for CCCC
Current profitability levels for the company are sitting at:
- -3.54 for the present operating margin
- 0.77 for the gross margin
The net margin for C4 Therapeutics Inc stands at -3.13. The total capital return value is set at -0.36. Equity return is now at value -46.00, with -29.76 for asset returns.
Based on C4 Therapeutics Inc (CCCC), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -1.06.
Currently, EBITDA for the company is -122.1 million with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 10.12. The receivables turnover for the company is 3.26for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.31.
Conclusion
To wrap up, the performance of C4 Therapeutics Inc (CCCC) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
